Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Up 0.5% – What’s Next?

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) shot up 0.5% during trading on Thursday . The company traded as high as $6.58 and last traded at $6.45. 3,646,349 shares were traded during trading, a decline of 76% from the average session volume of 14,902,363 shares. The stock had previously closed at $6.42.

Wall Street Analysts Forecast Growth

A number of research firms have commented on RXRX. KeyCorp reduced their price objective on shares of Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating for the company in a research report on Wednesday, January 8th. Needham & Company LLC reissued a “buy” rating and set a $11.00 target price on shares of Recursion Pharmaceuticals in a report on Wednesday, December 11th. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat.com, Recursion Pharmaceuticals has a consensus rating of “Hold” and an average target price of $8.75.

Recursion Pharmaceuticals Stock Up 2.0 %

The company has a quick ratio of 4.35, a current ratio of 4.35 and a debt-to-equity ratio of 0.04. The company has a market cap of $2.55 billion, a price-to-earnings ratio of -4.27 and a beta of 0.85. The stock has a fifty day moving average price of $6.90 and a two-hundred day moving average price of $6.95.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.01). The company had revenue of $26.08 million during the quarter, compared to analyst estimates of $12.62 million. Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The firm’s revenue for the quarter was up 147.6% compared to the same quarter last year. During the same period last year, the firm earned ($0.43) EPS. As a group, sell-side analysts expect that Recursion Pharmaceuticals, Inc. will post -1.56 EPS for the current year.

Insider Buying and Selling at Recursion Pharmaceuticals

In other Recursion Pharmaceuticals news, CFO Michael Secora sold 15,000 shares of Recursion Pharmaceuticals stock in a transaction dated Wednesday, November 13th. The stock was sold at an average price of $7.66, for a total value of $114,900.00. Following the transaction, the chief financial officer now owns 1,499,631 shares in the company, valued at $11,487,173.46. The trade was a 0.99 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $7.64, for a total value of $87,455.08. Following the completion of the transaction, the director now owns 7,066,113 shares in the company, valued at approximately $53,985,103.32. This represents a 0.16 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 43,894 shares of company stock worth $317,139 over the last 90 days. Insiders own 15.75% of the company’s stock.

Institutional Trading of Recursion Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in RXRX. ARK Investment Management LLC grew its holdings in shares of Recursion Pharmaceuticals by 16.4% during the third quarter. ARK Investment Management LLC now owns 32,769,186 shares of the company’s stock worth $215,949,000 after purchasing an additional 4,626,268 shares during the last quarter. State Street Corp boosted its holdings in Recursion Pharmaceuticals by 47.1% in the third quarter. State Street Corp now owns 12,870,272 shares of the company’s stock valued at $84,815,000 after acquiring an additional 4,120,685 shares during the last quarter. Ghisallo Capital Management LLC bought a new stake in Recursion Pharmaceuticals in the second quarter valued at approximately $8,250,000. Perceptive Advisors LLC bought a new stake in Recursion Pharmaceuticals in the second quarter valued at approximately $5,769,000. Finally, Geode Capital Management LLC boosted its holdings in Recursion Pharmaceuticals by 13.7% in the third quarter. Geode Capital Management LLC now owns 5,431,911 shares of the company’s stock valued at $35,803,000 after acquiring an additional 656,003 shares during the last quarter. 89.06% of the stock is currently owned by institutional investors.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.